Nifedipine prevents iron accumulation and reverses iron-overload-induced dopamine neuron degeneration in the substantia nigra of rats

Neurotoxicity Research

Volumn 22, Issue 4, 2012, Pages 274-279

  Ma, Ze Gang ^a   Zhou, Yu ^a   Xie, Jun Xia ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Dopamine neuron; Iron; L type Ca2+ channel; Nifedipine

Indexed keywords

DOPAMINE; IRON DEXTRAN; NIFEDIPINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; ELECTROCHEMICAL ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; IRON OVERLOAD; MALE; NERVE CELL DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; TREATMENT RESPONSE;

ANALYSIS OF VARIANCE; ANIMALS; CALCIUM CHANNEL BLOCKERS; CELL COUNT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINERGIC NEURONS; IRON; IRON-DEXTRAN COMPLEX; MALE; NERVE DEGENERATION; NIFEDIPINE; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

RATTUS;

EID: 84870289577     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-012-9309-8     Document Type: Article

References (40)

1. Anantharam V, Lehrmann E, Kanthasamy A, Yang Y, Banerjee P, Becker KG, Freed WJ, Kanthasamy AG (2007) Microarray analysis of oxidative stress regulated genes in mesencephalic dopaminergic neuronal cells: relevance to oxidative damage in Parkinson's disease. Neurochem Int 50:834-847
2. Andrews NC (1999) Disorders of iron metabolism. N Engl J Med 341:1986-1995
3. Berg D, Hochstrasser H (2006) Iron metabolism in Parkinsonian syndromes. Mov Disord 21:1299-1310
4. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65:135- 172
5. Bradbury MW (1997) Transport of iron in the blood-brain-cerebrospinal fluid system. J Neurochem 69:443-454
6. Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, Meredith GE, Surmeier DJ (2007) 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 447: 1081-1086
7. De Waard M, Gurnett CA, Campbell KP (1996) Structural and functional diversity of voltage-activated calcium channels. Ion Channels 4:41-87
8. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52:1830-1836
9. Faucheux BA, Hirsch EC, Villares J, Selimi F, Mouatt-Prigent A, Javoy-Agid F, Hauw JJ, Agid Y (1993) Distribution of 125Iferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson's disease. J Neurochem 60:2338-2341
10. Faucheux BA, Bonnet AM, Agid Y, Hirsch EC (1999) Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 353:981-982
11. Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC (2003) Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem 86:1142-1148
12. Gaasch JA, Geldenhuys WJ, Lockman PR, Allen DD, Van der Schyf CJ (2007) Voltage-gated calcium channels provide an alternate route for iron uptake in neuronal cell cultures. Neurochem Res 32:1686-1693
13. Gotz ME, Double K, Gerlach M, Youdim MB, Riederer P (2004) The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 1012:193-208
14. He Y, Lee T, Leong SK (1999) Time-course and localization of transferrin receptor expression in the substantia nigra of 6-hydroxydopamine-induced parkinsonian rats. Neuroscience 91:579-585
15. Jellinger K, Kienzl E, Rumpelmair G, Riederer P, Stachelberger H, Ben-Shachar D, Youdim MB (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J Neurochem 59:1168-1171
16. Jiang H, Luan Z, Wang J, Xie J (2006) Neuroprotective effects of iron chelator desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload. Neurochem Int 49:605-609
17. Jiang H, Song N, Wang J, Ren LY, Xie JX (2007) Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra. Neurochem Int 51:32-36
18. Ke Y, Ming Qian Z (2003) Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2:246-253
19. Koprich JB, Reske-Nielsen C, Mithal P, Isacson O (2008) Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflamm 5:8
20. Kupsch A, Sautter J, Schwarz J, Riederer P, Gerlach M, Oertel WH (1996) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res 741:185-196
21. Legssyer R, Geisser P, McArdle H, Crichton RR, Ward RJ (2003) Comparison of injectable iron complexes in their ability to iron load tissues and to induce oxidative stress. Biometals 16: 425-433
22. Ligon B, Boyd AE 3rd, Dunlap K (1998) Class A calcium channel variants in pancreatic islets and their role in insulin secretion. J Biol Chem 273:13905-13911
23. Linazasoro GJ (2002) Neuroprotection in Parkinson's disease: love story or mission impossible? Expert Rev Neurother 2:403-416
24. Lockman JA, Geldenhuys WJ, Bohn KA, Desilva SF, Allen DD, Van der Schyf CJ (2012) Differential effect of nimodipine in attenuating iron-induced toxicity in brain- and blood-brain barrier-associated cell types. Neurochem Res. doi:10.1007/ s11064-011-0591-2
25. Ma ZG, Wang J, Jiang H, Liu TW, Xie JX (2007) Myricetin reduces 6-hydroxydopamine-induced dopamine neuron degeneration in rats. Neuroreport 18:1181-1185
26. Meissner W, Hill MP, Tison F, Gross CE, Bezard E (2004) Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends Pharmacol Sci 25:249-253
27. Moldzio R, Radad K, Duvigneau JC, Kranner B, Krewenka C, Piskernik C, Rausch WD (2006) Glutamate-induced cell death and formation of radicals can be reduced by lisuride in mesencephalic primary cell culture. J Neural Transm 113: 1095-1105
28. Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, Yazdanpanah M, Wilson GJ, Schwartz A, Liu PP, Backx PH (2003) L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 9:1187-1194
29. Peri R, Triggle DJ, Singh S (2001) Regulation of L-type calcium channels in pituitary GH(4)C(1) cells by depolarization. J Biol Chem 276:31667-31673
30. Qian ZM, Shen X (2001) Brain iron transport and neurodegeneration. Trends Mol Med 7:103-108
31. Rouault TA (2001) Iron on the brain. Nat Genet 28:299-300 Schipper HM (1999) Glial HO-1 expression, iron deposition and oxidative stress in neurodegenerative diseases. Neurotox Res 1:57-70
32. Schurr A (2004) Neuroprotection against ischemic/hypoxic brain damage: blockers of ionotropic glutamate receptor and voltage sensitive calcium channels. Curr Drug Targets 5:603-618
33. Tsushima RG, Wickenden AD, Bouchard RA, Oudit GY, Liu PP, Backx PH (1999) Modulation of iron uptake in heart by L-type Ca2+ channel modifiers: possible implications in iron overload. Circ Res 84:1302-1309
34. Wang SQ, Song LS, Lakatta EG, Cheng H (2001) Ca2+ signalling between single L-type Ca2+ channels and ryanodine receptors in heart cells. Nature 410:592-596
35. Wang J, Jiang H, Xie JX (2004) Time dependent effects of 6-OHDA lesions on iron level and neuronal loss in rat nigrostriatal system. Neurochem Res 29:2239-2243
36. Xu HM, Jiang H, Wang J, Luo B, Xie JX (2008) Over-expressed human divalent metal transporter 1 is involved in iron accumulation in MES23.5 cells. Neurochem Int 52:1044-1051
37. Youdim MB, Stephenson G, Ben Shachar D (2004) Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 1012:306-325
38. Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, Giaveri G, Arosio P, Santambrogio P, Fariello RG, Karatekin E, Kleinman MH, Turro N, Hornykiewicz O, Zucca FA (2004a) The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci USA 101:9843-9848
39. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004b) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5:863-873
40. Zhang L, Lee T, Wang Y, Soong TW (2000) Heterologous expression, functional characterization and localization of two isoforms of the monkey iron transporter Nramp2. Biochem J 349:289-297